Dualitas Therapeutics
PrivateLast Round
Series A
Sep 16, 2025
Est. Valuation
$87M
Total Funding Raised
$65M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Dualitas Therapeutics operates in Healthcare & Life Sciences and is based in South San Francisco, California. Its latest recorded funding round was a Series A round in September 2025.
Dualitas Therapeutics is a biotechnology company that develops next-generation bispecific antibody therapies for immunology and inflammation.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Dualitas Therapeutics Comparables
Compare Dualitas Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Cantai Therapeutics | 82% | |
| InduPro | 81% | |
| Epana Bio | 78% |
For institutional investors. Book with your work email.
Dualitas Therapeutics Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Dualitas Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| SV Health Investors | Seed, Series A |
| Chugai Venture Fund | Series A |
| Versant Ventures | Series A |
| Alexandria Venture Investments | Series A |
| Qiming | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 9, 2026
Open roles increased to 6, representing 29% of headcount.
- Oct 19, 2026
Open roles increased to 6, 3.7x the trailing average.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingSep 18, 2026
Dualitas Therapeutics, Inc. collaborates with Roche to discover and develop novel bispecific antibodies for immunology and inflammation diseases, screening over 300,000 combinations while Roche handles subsequent preclinical development, regulatory, manufacturing, and commercial activities, on Sep 23rd '26.
- signs_new_clientSep 17, 2026
On Sep 17th '26, Roche turns to Dualitas Therapeutics, Inc. to find new bispecific approaches for immunology in a deal involving screening 300,000 new combinations.
- receives_financingSep 17, 2026
Dualitas Therapeutics, Inc. will receive $36.5M in upfront payments from Roche under a partnership to screen more than 300,000 bispecific antibody combinations, with eligibility for research, development and commercial milestone payments and tiered royalties that could bring the deal’s total value to up to $1 billion.
For institutional investors. Book with your work email.
Dualitas Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Dualitas Therapeutics's valuation, stock price, and market status.
Is Dualitas Therapeutics a public or private company?
Dualitas Therapeutics is a private company.
What is the current stock price of Dualitas Therapeutics?
Dualitas Therapeutics is a private company, so its shares have no public market price. Caplight tracks Dualitas Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Dualitas Therapeutics worth (valuation)?
Dualitas Therapeutics's valuation is estimated at $87.0M based on funding round data.
Can I buy Dualitas Therapeutics stock?
Dualitas Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Dualitas Therapeutics's last funding round?
Dualitas Therapeutics's most recent funding round was Series A on September 16, 2025.
Who are the main investors in Dualitas Therapeutics?
Key investors in Dualitas Therapeutics include Versant Ventures, Qiming.
Will Dualitas Therapeutics IPO soon?
No public IPO plans have been announced for Dualitas Therapeutics.
How can I track Dualitas Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Dualitas Therapeutics's shares on secondary markets.